STENOCARE A/S (“STENOCARE” or the “Company”) published its Q4 2025 report on February 26.

The following are some key points that we have chosen to highlight in connection with the report:

The growth trend continued
Strong development in Denmark
Acquisition of CannGros is expected to strengthen growth and profitability significantly
Reaches positive EBITDA for the third consecutive quarter

In conclusion, STENOCARE delivered another strong quarter in Q4-25, with net sales increasing by 107% Y-Y and full-year growth reaching 215%, primarily driven by continued strong momentum in Denmark and gradual traction for the Astrum 10-10 oil. The Company achieved positive EBITDA for the third consecutive quarter, supported by solid cost control under the STENOCARE 3.0 strategy and a leaner operating structure. While cash flow was negatively impacted by working capital effects related to rapid growth, this is viewed largely as a timing effect. The acquisition of CannGros is expected to significantly strengthen both growth and profitability in 2026, adding DKK 4–6m in projected revenue with limited incremental costs and positioning STENOCARE as the market leader in Denmark across both oil and flower segments. Overall, STENOCARE appears well positioned for continued growth, improved profitability, and strengthening strategic positioning across key European markets in 2026.

Read Analyst Group’s comment on the report here

About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.Read more about Analyst Group This is a press release from Analyst Group regarding the publication of a comment on STENOCARE. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.